Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker AP, Weidhaas J. The KRAS-variant and miRNA expression in RTOG endometrial cancer clinical trials 9708 and 9905
. PLoS One. 2014;9(4):e94167.
Klopp A, Smith BD, Alektiar K, Cabrera A, Damato AL, Erickson B, Fleming G, Gaffney D, Greven K, Lu K, Miller D, Moore D, Petereit D, Schefter T, Small W Jr, Yashar C, Viswanathan AN. The role of postoperative radiation therapy for endometrial cancer: executive summary of an American Society for Radiation Oncology evidence-based guideline
. Pract Radiat Oncol. 2014;4(3):137-144.
Garg S, Kilburn JM, Randolph DM, Lucas JT, Urbanic JJ, Porosnicu M, Hinson WH, Kearns WT, Greven KM. Re-irradiation for second primary or recurrent cancers of the head and neck: composite dosimetric measures to evaluate dose to the carotid arteries [abstract]. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl):S480-S481.
Rustin GJS, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A, Kristensen G, Jakobsen A, Greven K, et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
. Int J Gynecol Cancer. 2011;21(2):419-423.
Lee LJ, Winter K, Ratner E, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Weidhaas J. The KRAS-variant and outcome in endometrial adenocarcinoma: combined analysis of RTOG 9708 and 9905 [abstract]. Int J Radiat Oncol Biol Phys. 2010;78(3 Suppl):S402.
Greven KM. Resolving the confusion surrounding adjuvant radiation in endometrial cancer [commentary]. Oncology (Williston Park). 2009;23(4):353,356.
Greven K. Can serial PET/CT imaging during and after chemoradiation treatment assist in individualizing therapy for patients with squamous cell cancer of the head and neck? [abstract]. J Clin Oncol. 2009;27(15 Suppl):e17022.
Saconn PA, Greven K, Gee C, Greven C, McCoy T, Ekstrand K. Alternative dose for choroidal melanoma treated with an iodine 125 radioactive plaque: a single institution retrospective study [abstract]. Int J Radiat Oncol Biol Phys. 2008;72(1 Suppl):S415-S416.
Greven KM, Greven CM. Orbital, ocular, and optic nerve tumors In: Gunderson LL, Tepper JE, eds. Clinical radiation oncology. 2nd ed. Philadelphia: Elsevier Churchill Livingstone;2007: 613-628.
Small W, Winter K, Levenback C, Iyer R, Hymes S, Jhingren A, Gaffney D, Erickson B, Greven K. Extended field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of Arm 2 of RTOG 0116 [abstract]. Int J Radiat Oncol Biol Phys. 2007;69(3 Suppl):S5-S6.
Gaffney DK, Winter K, Dicker AP, Miller B, Eifel PJ, Ryu J, Avizonis V, Fromm M, Greven K. Celebrex (Celecoxib) and chemoradiation in patients with locally advanced cervical cancer. An efficacy report of RTOG 0128 [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S41.
Greven KM, Williams WD, Browne JD, McGuirt WF, D'Agostino R Jr. Complete clinical response on post treatment CT imaging eliminates the need for adjuvant neck dissection following treatment for node positive head and neck cancer [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S440.
Lee W, Bae K, Lawton C, Gillin M, Morton G, Firat S, Baikadi M, Greven K, Kuettel M, Sandler H. Biochemical recurrence and late toxicity following external beam radiotherapy combined with permanent source prostate brachytherapy: analysis of RTOG 0019 [abstract]. Int J Radiat Oncol Biol Phys. 2006;66(3 Suppl):S57.
For a listing of recent publications, refer to PubMed, a service provided by the National Library of Medicine.
For a list of earlier publications, visit the Carpenter Library Publication Search.
Professor, Radiation Oncology
Carcinoma of the Eye and Ocular Adnexa, Gynecologic Malignancies, Head and Neck Cancers, Total Body Irradiation for Bone Marrow Transplants, General Radiation Oncology, Radiation Oncology
The overall Patient Rating score is the average of responses to the nine questions listed below. The questions are from the Press Ganey Patient Satisfaction Survey. Responses are measured on a 1 to 5 scale, where 1 represents "very poor" and 5 represents "very good."
Comments are taken from the Care Provider section of the Press Ganey Patient Satisfaction Survey. Comments are posted exactly as they are written. Comments are added weekly. To protect patient privacy and confidentiality, patient names are not included.
Never had a bad experience
#8. Plenty of time.
They was very nice. They answered every question that we ask.
*Dr. Greven was respectful and calm in her approach to my issues and to the discussion we had. I was confident in what she had to say.
She is the best and I wouolodn't want anyone else tending to me care.